Omnicef

Omnicef

cefdinir

Manufacturer:

Pfizer

Distributor:

DKSH
Full Prescribing Info
Contents
Cefdinir.
Description
Cefdinir is an oral cephem antibiotic which has a vinyl group at the 3-position and a 2-aminothiazolyl hydroxyimino group at the 7-position of 7-aminocephalosporanic acid.
Action
Pharmacology: Antibacterial Activity: Cefdinir has broad-spectrum activity against gram-positive and gram-negative microorganisms. In particular, in comparison with the other oral cephems, it has potent activity against such gram-positive microorganisms as Staphylococcus and Streptococcus spp. Its mechanism of action is bactericidal. It is stable to β-lactamase produced by many organisms, and has good activity against β-lactamase-producing organisms.
Mechanism of Action: Its mechanism of action is inhibition of cell wall synthesis. It has high affinity for penicillin-binding proteins (PBP) 1(1a, 1b), 2 and 3, with the site of activity varying according to organism.
Indications/Uses
Treatment of the following infections caused by Omnicef-susceptible strains of Staphylococcus sp, Streptococcus sp, Streptococcus pneumoniae, Peptostreptococcus and Propionibacterium spp, Neisseria gonorrhoeae, Branhamella catarrhalis, Escherichia coli, Klebsiella sp, Proteus mirabilis, Providencia sp and Haemophilus influenzae: Folliculitis, furuncle, furunculosis, carbuncle, impetigo contagiosa, erysipelas, phlegmon, lymphangitis (lymphadenitis), felon, suppurative paronychia, subcutaneous abscess, hidradenitis, infectious atheroma, chronic pyoderma.
Pyelonephritis, cystitis.
Uterine adnexitis, intrauterine infection, bartholinitis.
Dosage/Direction for Use
Adults: 100 mg (potency) of cefdinir every 8 hrs orally.
Children: The recommended dosage and duration of treatment for children are described for various infections or by body weight in the following table. The total daily dose for all infections is 14 mg/kg. (See table.)

Click on icon to see table/diagram/image

The dosage may be adjusted depending on the patient's age and symptoms. Maximum daily dose of cefdinir is 600 mg.
Contraindications
Patients with a history of shock due to any ingredient of Omnicef. Patients with a history of hypersensitivity to any ingredients of Omnicef or other cephem antibiotics.
Special Precautions
General: Careful inquiry about any form of hypersensitivity should be made, since reactions eg, shock may occur.
Careful administration is required in patients with: History of hypersensitivity to penicillins; personal or familial predisposition to allergic reactions eg, bronchial asthma, rash or urticaria; serious renal function disorder; poor oral nutrition, receiving parenteral nutrition, elderly or patients in a debilitated state. (Careful observation is essential in these patients as vitamin K deficiency symptoms may develop.)
Use in pregnancy: The safety of cefdinir in pregnant women has not been established. Therefore, cefdinir should only be used in pregnant women and women suspected of being pregnant, provided that the expected therapeutic benefits are evaluated to outweigh the possible risk of treatment.
Adverse Reactions
Shock: It may occur rarely. Patients should be carefully observed, and therapy discontinued, in the event of symptoms eg, discomfort, paresthesias of the mouth, wheezing, vertigo, desire to defecate, tinnitus or diaphoresis, etc.
Hypersensitivity: If signs of hypersensitivity reactions eg, rash, urticaria, erythema, pruritus or fever occur, Omnicef should be discontinued and appropriate measures should be taken.
Hematologic: Granulocytopenia or eosinophilia may occur infrequently. Omnicef should be discontinued if any of these abnormalities is found. It has been reported that hemolytic anemia has occurred with other cephem antibiotics.
Hepatic: Infrequently, an increase in GOT, GPT or alkaline phosphatase may occur.
Renal: Infrequently, an increase in BUN may occur. It has been reported that serious renal impairment eg, acute renal insufficiency, may rarely occur with other cephem antibiotics. If any of these abnormalities is found, discontinuation of Omnicef and appropriate measures should be taken.
Gastrointestinal: It has been reported that serious colitis eg, pseudomembranous colitis, manifested by blood in stools, may occur with other cephem antibiotics. Infrequently nausea, diarrhea, abdominal pain, stomach discomfort, heartburn or anorexia, and rarely constipation may occur.
Respiratory: It has been reported that interstitial pneumonia or PTE syndrome, manifested by fever, cough dyspnea, abnormal x-ray or eosinophilia, may rarely occur with other cephem antibiotics. If any such symptoms occur, Omnicef should be discontinued and appropriate measures eg, giving adrenocortical hormones should be taken.
Substituted Microbism: Rarely, stomatitis or candidiasis may occur.
Avitaminosis: Rarely, vitamin K deficiencies (eg, hypoprothrombinemia or bleeding tendencies) or vitamin B-group deficiencies (eg, glossitis, stomatitis, anorexia or neuritis) may occur.
Others: Rarely, headache, dizziness or chest pressure sensation may occur.
Drug Interactions
Action of cefdinir may diminish as a result of reduced oral availability by the concomitant use with iron preparations and antacids.
Influences on Laboratory Values: False-positive results may occur in urine sugar tests with Benedict's solution, Fehling's solution and Clinitest.
False-positives have not been reported with Tes-Tape. A positive direct Coombs' test may occur.
MIMS Class
ATC Classification
J01DD15 - cefdinir ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Cap 100 mg x 10 x 10's. Oral susp 125 mg/5 mL x 30 mL.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in